Health

Even “Moderate” Drinking Raises Lifetime Health Risks

Even alcohol consumption commonly considered “moderate” was associated with increased lifetime risks of death and disease, with no evidence of a net protective health effect at low levels of drinking. Researchers estimated alcohol-attributable mortality and morbidity risks in the US by integrating data from national health surveys, U.S. Census population statistics, Centers for Disease Control and Prevention mortality records, and Institute for Health Metrics and Evaluation disease burden data. The analysis found that lifetime alcohol-related mortality risk exceeded 1 in 1,000 among men consuming more than 6.5 drinks per week and women consuming more than 7 drinks per week, and rose to greater than 1 in 100 at more than 8.5 drinks per week for both sexes. At 14 drinks per week—the former upper limit recommended in U.S. dietary guidelines for men—the estimated risk of an alcohol-caused death reached 1 in 25 (4%). Drinking patterns also mattered: consuming more than one drink per occasion was linked to progressively higher risks of breast cancer, cardiovascular disease, and injury. The findings suggest that even relatively low levels of alcohol intake can adversely affect long-term health and support updated guidance recommending that adult drinkers limit alcohol consumption to no more than one drink per day, regardless of sex. Source: https://www.jsad.com/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

21 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

23 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.